| Identification | Back Directory | [Name]
AF12198 | [CAS]
185413-30-3 | [Synonyms]
AF12198
AC-PHE-GLU-TRP-THR-PRO-GLY-TRP-TYR-GLN-AZE-TYR-ALA-LEU-PRO-LEU-NH2
AC-PHE-GLU-TRP-THR-PRO-GLY-TRP-TYR-GLN-L-AZETIDINE-2-CARBONYL-TYR-ALA-LEU-PRO-LEU-NH2
AC-PHE-GLU-TRP-THR-PRO-GLY-TRP-TYR-GLN-L-AZETIDINE-2-CARBOXYLIC ACID-TYR-ALA-LEU-PRO-LEU-NH2 | [Molecular Formula]
C96H123N19O22 | [MDL Number]
MFCD02259571 | [MOL File]
185413-30-3.mol | [Molecular Weight]
1895.12 |
| Chemical Properties | Back Directory | [Melting point ]
>179°C (dec.) | [density ]
1.353±0.06 g/cm3(Predicted) | [storage temp. ]
−20°C
| [solubility ]
DMSO (Slightly), Methanol (Slightly), Water (Very Slightly) | [form ]
solid
| [pka]
4.44±0.10(Predicted) | [color ]
White to Off-White | [Sequence]
Ac-Phe-Glu-Trp-Thr-Pro-Gly-Trp-Tyr-Gln-{Aze}-Tyr-Ala-Leu-Pro-Leu-NH2 |
| Hazard Information | Back Directory | [Uses]
AF 12198 is a peptide that selectively binds Interleukin-1 (IL-1) receptor and blocks in vivo responses to IL-1 (1). The interleukin-1 receptor can activate the innate immune response by binding to cytokines (2). Dysregulation of cytokine production can lead to aberrant immune cells activation that could result in auto-inflammatory disorders. | [in vivo]
AF12198 (intravenous infusion; 16 mg/kg; 30 min before LPS intravenous injection) significantly attenuates the increase in lung MPO activity induced by LPS in acute lung inflammation and it reduces the lung microvascular leakage from rats inflamed with LPS at the 4 h (32.6%), 12 h (50.1%) and 24 h (65.3%) after LPS[2]. | Animal Model: | Male Wistar rats[2] | | Dosage: | 16?mg/kg | | Administration: | Intravenous infusion; 30?min before LPS intravenous injection | | Result: | Decreased pulmonary microvascular leakage in rats. |
| [IC 50]
IL-6; IL-8; IL1R1: 8 nM (IC50) | [storage]
Store at -20°C |
|
|